Prelude Therapeutics Incorporated - Common Stock — Quarterly Financial Statistics (NASDAQ:PRLD) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -34.23 M-26.07 M-19.11 M23.12 M-21.68 M -43.76 M Cash from investing activities 62.19 M11.52 M40.09 M-60.34 M8.5 M -228 K Cash from financing activities -160 K37 K-5 00024.94 M-314 K 24.66 M Free cash flow -34.23 M-26.07 M-19.11 M23.12 M-21.68 M -43.76 M

News

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet

Prelude Therapeutics files to offer up to $25 million in stock through Jefferies

Citizens raises Prelude Therapeutics price target on JAK2 potential

Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens

Prelude Therapeutics stock surges after FDA clears IND for cancer drug

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens

Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus

Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens

Earnings call transcript: Prelude Therapeutics Q3 2025 sees stock steadiness

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.56%